Morphotek Inc.'s promising ovarian cancer drug farletuzumab yielded disappointing results in a Phase III trial in ovarian cancer. The study, which combined farletuzumab with carboplatin and taxane in platinum-sensitive epithelial ovarian cancer, did not meet its primary endpoint of progression-free survival (PFS).